![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MS4A12 |
Gene summary for MS4A12 |
![]() |
Gene information | Species | Human | Gene symbol | MS4A12 | Gene ID | 54860 |
Gene name | membrane spanning 4-domains A12 | |
Gene Alias | Ms4a10 | |
Cytomap | 11q12.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9NXJ0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54860 | MS4A12 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.26e-04 | -2.12e-01 | 0.0155 |
54860 | MS4A12 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.69e-12 | 1.06e+00 | -0.1954 |
54860 | MS4A12 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.84e-02 | 1.02e+00 | -0.2196 |
54860 | MS4A12 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.35e-04 | 4.63e-01 | -0.1464 |
54860 | MS4A12 | HTA11_5212_2000001011 | Human | Colorectum | AD | 5.27e-15 | 2.26e+00 | -0.2061 |
54860 | MS4A12 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.14e-03 | -2.12e-01 | 0.096 |
54860 | MS4A12 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.25e-05 | -2.12e-01 | 0.0674 |
54860 | MS4A12 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.53e-02 | -2.02e-01 | 0.294 |
54860 | MS4A12 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.20e-02 | -2.08e-01 | 0.3859 |
54860 | MS4A12 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 8.62e-04 | -2.12e-01 | 0.3005 |
54860 | MS4A12 | A002-C-010 | Human | Colorectum | FAP | 9.36e-06 | -2.09e-01 | 0.242 |
54860 | MS4A12 | A002-C-201 | Human | Colorectum | FAP | 4.25e-05 | -2.12e-01 | 0.0324 |
54860 | MS4A12 | A002-C-203 | Human | Colorectum | FAP | 9.04e-05 | -2.06e-01 | 0.2786 |
54860 | MS4A12 | A002-C-205 | Human | Colorectum | FAP | 1.12e-02 | -2.01e-01 | -0.1236 |
54860 | MS4A12 | A002-C-116 | Human | Colorectum | FAP | 4.02e-02 | -2.01e-01 | -0.0452 |
54860 | MS4A12 | A014-C-008 | Human | Colorectum | FAP | 3.72e-02 | -2.12e-01 | -0.191 |
54860 | MS4A12 | F034 | Human | Colorectum | FAP | 8.62e-04 | -2.12e-01 | -0.0665 |
54860 | MS4A12 | F072B | Human | Colorectum | FAP | 3.85e-03 | -2.12e-01 | 0.257 |
54860 | MS4A12 | CRC-1-8810 | Human | Colorectum | CRC | 4.25e-05 | -2.12e-01 | 0.6257 |
54860 | MS4A12 | CRC-3-11773 | Human | Colorectum | CRC | 4.07e-04 | -2.12e-01 | 0.2564 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MS4A12 | SNV | Missense_Mutation | c.797C>A | p.Pro266His | p.P266H | Q9NXJ0 | protein_coding | deleterious(0) | possibly_damaging(0.575) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
MS4A12 | SNV | Missense_Mutation | novel | c.556N>G | p.Asn186Asp | p.N186D | Q9NXJ0 | protein_coding | deleterious(0.01) | possibly_damaging(0.769) | TCGA-AP-A1E1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MS4A12 | SNV | Missense_Mutation | novel | c.377N>A | p.Ala126Asp | p.A126D | Q9NXJ0 | protein_coding | deleterious(0.01) | possibly_damaging(0.883) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
MS4A12 | SNV | Missense_Mutation | c.413C>A | p.Ser138Tyr | p.S138Y | Q9NXJ0 | protein_coding | tolerated(0.29) | possibly_damaging(0.758) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
MS4A12 | SNV | Missense_Mutation | c.506N>A | p.Ser169Tyr | p.S169Y | Q9NXJ0 | protein_coding | deleterious(0) | possibly_damaging(0.855) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MS4A12 | SNV | Missense_Mutation | c.755N>A | p.Ser252Tyr | p.S252Y | Q9NXJ0 | protein_coding | tolerated(0.07) | benign(0.142) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MS4A12 | SNV | Missense_Mutation | novel | c.336N>G | p.Ile112Met | p.I112M | Q9NXJ0 | protein_coding | tolerated(0.5) | benign(0.005) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MS4A12 | SNV | Missense_Mutation | novel | c.137C>T | p.Ala46Val | p.A46V | Q9NXJ0 | protein_coding | tolerated(0.08) | benign(0.03) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
MS4A12 | SNV | Missense_Mutation | novel | c.117A>T | p.Leu39Phe | p.L39F | Q9NXJ0 | protein_coding | tolerated(0.71) | benign(0.154) | TCGA-DD-AACI-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
MS4A12 | SNV | Missense_Mutation | c.413C>A | p.Ser138Tyr | p.S138Y | Q9NXJ0 | protein_coding | tolerated(0.29) | possibly_damaging(0.758) | TCGA-05-4420-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |